Alteration of N-glycome in diethylnitrosamine-induced hepatocellular carcinomamice: A non-invasivemonitoring tool for liver cancer

Liver International

Volumn 30, Issue 8, 2010, Pages 1221-1228

  Liu, Xue En ^a,b   Dewaele, Sylviane ^b   Vanhooren, Valerie ^b   Fan, Ye Dong ^c   Wang, Ling ^a   Van Huysse, Jacques ^c   Zhuang, Hui ^a   Contreras, Roland ^b   Libert, Claude ^b   Chen, Cuiying Chitty ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

DENA; Hepatocellular carcinoma (HCC); Marker; N glycan

Indexed keywords

ALPHA 1,6 FUCOSYLTRANSFERASE 8; DIETHYLNITROSAMINE; FUCOSYLTRANSFERASE; GLYCAN; MGAT4A; POLYSACCHARIDE; SODIUM CHLORIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE SYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; ELECTROPHORESIS; FEMALE; FOLLOW UP; FUCOSYLATION; GENETIC TRANSCRIPTION; LIVER CELL CARCINOMA; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT MONITORING; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; DNA PRIMERS; DNA, COMPLEMENTARY; ELECTROPHORESIS; FUCOSYLTRANSFERASES; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79951587181     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02279.x     Document Type: Article

References (26)

1. Becker RA, Shank RC. Kinetics of formation and persistence of ethylguanines in DNA of rats and hamsters treated with diethylnitrosamine. Cancer Res 1985; 45: 2076-84.
2. Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-11.
3. Jaeken J, Carchon H. Congenital disorders of glycosylation: a booming chapter of pediatrics. Curr Opin Pediatr 2004; 16: 434-9.
4. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4: 477-88.
5. Freeze HH, Westphal V. Balancing N-linked glycosylation to avoid disease. Biochimie 2001; 83: 791-9.
6. Axford JS. Glycosylation and rheumatic disease. Biochim Biophys Acta 1999; 1455: 219-29.
7. Peracaula R, Tabares G, Royle L, et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003; 13: 457-70.
8. Liu XE, Desmyter L, Gao CF, et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007; 46: 1426-35.
9. Chen C, Schmilovitz-Weiss H, Liu XE, et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 2009; 8: 463-70.
10. Vanderschaeghe D, LaroyW, Sablon E, et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009; 8: 986-94.
11. Callewaert N, Van Vlierberghe H, Van Hecke A, et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429-34.
12. Vanhooren V, Laroy W, Libert C, Chen C. N-glycan profiling in the study of human aging. Biogerontology 2008; 9: 351-6.
13. Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc 2006; 1: 397-405.
14. Wang X, Gu J, Ihara H, et al. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 2006; 281: 2572-7.
15. Dwek RA. Biological importance of glycosylation. Dev Biol Stand 1998; 96: 43-7.
16. Trombetta ES, Parodi AJ. Glycoprotein reglucosylation. Methods 2005; 35: 328-37.
17. Wang X, Inoue S, Gu J, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA 2005; 102: 15791-6.
18. Hann B, Balmain A. Building 'validated' mouse models of human cancer. Curr Opin Cell Biol 2001; 13: 778-84.
19. Leenders MW, Nijkamp MW, Borel Rinkes IH. Mouse models in liver cancer research: a review of current literature. World J Gastroenterol 2008; 14: 6915-23.
20. Narasimhan S, Schachter H, Rajalakshmi S. Expression of N-acetylglucosaminyltransferase III in hepatic nodules during rat liver carcinogenesis promoted by orotic acid. J Biol Chem 1988; 263: 1273-81.
21. Nishikawa A, Fujii S, Sugiyama T, Hayashi N, Taniguchi N. High expression of an N-acetylglucosaminyltransferase III in 30-methyl DAB-induced hepatoma and ascites hepatoma. Biochem Biophys Res Commun 1988; 152: 107-12.
22. Nishikawa A, Gu J, Fujii S, Taniguchi N. Determination of N-acetylglucosaminyltransferases III, IV and V in normal and hepatoma tissues of rats. Biochim Biophys Acta 1990; 1035: 313-8.
23. Miyoshi E, Nishikawa A, Ihara Y, et al. N-acetylglucosaminyltransferase III and V messenger RNA levels in LEC rats during hepatocarcinogenesis. Cancer Res 1993; 53: 3899-902.
24. Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H. Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 610-9.
25. Yang X, Bhaumik M, Bhattacharyya R, et al. New evidence for an extra-hepatic role of N-acetylglucosaminyltransferase III in the progression of diethylnitrosamine-induced liver tumors in mice. Cancer Res 2000; 60: 3313-9.
26. Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N. Core fucose and bisecting GlcNAc, the direct modifiers of the Nglycan core: their functions and target proteins. Carbohydr Res 2009; 344: 1387-90.